Lilly raises 2026 revenue outlook after 39% sales growth

Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39% from a year earlier, and raised its full-year revenue forecast to $91 billion to $92 billion as sales volume growth more than offset lower realized prices. The company said sales volume rose 53% during the quarter while realized prices fell 15%. Demand for its diabetes and weight-loss drugs Mounjaro and Zepbound drove much of the growth. Mounjaro revenue increased 65% to $10.7 billion, while Zepbound revenue rose 49% to $5.35 billion. The revised revenue forecast compares with Lilly’s previous range of $85 billion to $87 billion. It is the company’s third increase to its 2026 revenue guidance this year. Lilly also raised its underlying full-year adjusted earnings outlook by $4.07 per share at the midpoint, but its updated adjusted earnings forecast is $35 to $36 per share, down from $35.50 to $36.50, after acquisition-related charges. Lilly reported third-quarter earnings per share of $7.22 and adjusted earnings per share of $7.48. Both figures included $4.57 per share in acquired in-process research and development charges, compared with $0.71 a year earlier. The company completed its AtaiBeckley...